Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.43 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.40 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.40 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.40 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.40 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9726057 | 0.86 | CYP4F2 (0.53) | CYP4F2CYP4A11CYP4Z1PLAAT3PLAAT5 | |
| SCHEMBL1375513 | 0.85 | CYP4F2 (0.51) | CYP4F2CYP4A11KMT2A | |
| SCHEMBL7059125 | 0.83 | MAPT (0.51) | CYP4F2CYP4A11PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL7057094 | 0.83 | PLAAT3 (0.58) | CYP4F2CYP4A11KYAT1PLAAT3PLAAT5 | |
| SCHEMBL304796 | 0.83 | L3MBTL1 (0.55) | CYP4F2CYP4A11PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL4871127 | 0.83 | CYP4F2 (0.72) | CYP4F2CYP4A11CYP4Z1L3MBTL1 | |
| SCHEMBL7060212 | 0.82 | F2RL1 (0.58) | CYP4F2CYP4A11PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL3941325 | 0.81 | ALDH1A1 (0.48) | CYP4F2CYP4A11CYP4Z1PLAAT3PLAAT5 | |
| Alcohol SCHEMBL28404120 | 0.80 | L3MBTL1 (0.52) | CYP4F2CYP4A11PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL4874395 | 0.80 | CYP4F2 (0.46) | CYP4F2CYP4A11CYP4Z1PLAAT3PLAAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608365-B1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | R TECH UENO LTD (JP) | 2013-10-02 | — | — | EP | disclosed |
| CN-1794988-B | Composition for treating vascular hyperpermeable disease | SUCAMPO AG | 2010-07-28 | — | — | CN | disclosed |
| CN-100491361-C | Thiazole derivatives and their use as VAP-1 inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 2009-05-27 | — | — | CN | disclosed |
| US-7442715-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-20060276521-A1 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-12-07 | — | — | US | disclosed |
| US-7125901-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-10-24 | — | — | US | disclosed |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-10-12 | — | — | US | disclosed |
| CN-1794988-A | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-06-28 | — | — | CN | disclosed |
| US-20060128770-A1 | Thiazole derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-06-15 | — | — | US | disclosed |
| CN-1761655-A | Thiazole derivatives and their use as VAP-1 inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 2006-04-19 | — | — | CN | disclosed |
| EP-1608365-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | Sucampo AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| EP-1587800-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS VAP-1 INHIBITORS | Astellas Pharma Inc. (JP) | 2005-10-26 | — | — | EP | disclosed |
| US-20040259923-A1 | Compound useful as cellular adhesion protein and as antiedemic agent | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-12-23 | — | — | US | disclosed |
| WO-2004087138-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004067521-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS VAP-1 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | VCAM1, ICAM1, VAPB | CYP4F2 3741/4885CYP4A11 2667/4885KYAT1 4452/4885 |
| US-20060276521-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | CYP4F2 3413/4885CYP4A11 3227/4885KYAT1 2196/4885 |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | VCAM1, VAPB, ICAM1 | CYP4F2 2773/4885CYP4A11 2827/4885KYAT1 2534/4885 |
| US-20060128770-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | CYP4F2 3413/4885CYP4A11 3227/4885KYAT1 2196/4885 |
| US-20040259923-A1 | Compound useful as cellular adhesion protein and as antiedemic agent | VCAM1, ICAM1, VAPB | CYP4F2 4694/4885CYP4A11 4346/4885KYAT1 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.